Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterized by highly elevated cholesterol levels and premature cardiovascular disease. If left untreated, those with heterozygous FH typically develop heart disease before age 55-60, while homozygotes develop heart disease in early life and die before age 20. Treatment involves intensive lifestyle management and maximum statin therapy to lower cholesterol levels, with additional drugs like ezetimibe as needed. For severe cases, lipoprotein apheresis can help lower cholesterol. Children with FH should be screened between ages 2-10 and treated early with statins to prevent heart disease later in life.
Serum Protein and Albumin-Globulin RatioASHIKH SEETHY
For MBBS Biochemistry Practical. Explains various methods of protein estimation and estimation of AG ratio, conditions leading to alterations in AG ratio etc.
Personalized medicine in Familial HypercholesterolaemiaDr. Julius Kwedhi
Familial hypercholesterolemia (FH) is an autosomal-dominant genetic disease present in all racial and ethnic groups and has long been recognized as a cause of premature atherosclerotic coronary heart disease.1–3 Heterozygous FH has the highest prevalence of genetic defects that cause significant premature mortality (≈1:200 to 1:500 or higher in founder populations).
The genetic basis of the disorder, impaired functioning of the low-density lipoprotein (LDL) receptor, was first recognized by Goldstein and Brown4 in their Nobel Prize–winning work.
Studies of LDL receptor function have identified additional mechanisms for the pathogenesis of FH (defects in apolipoprotein [apo] B impairing binding with the LDL receptor and gain-of-function mutations in proprotein convertase subtulisin/kexin type 9 [PCSK9] that enhance LDL receptor degradation).
FH leads to elevated LDL concentrations, with levels in heterozygous FH generally in untreated adults >190 mg/dL LDL cholesterol (LDL-C) and in untreated children or adolescents >160 mg/dL LDL-C. Long-term exposure to elevated plasma concentrations of LDL-C begins in utero, leading in heterozygotes to premature ischemic heart disease in mid adulthood and in homozygotes to ischemic heart disease in childhood or early adulthood.
A lysosomal storage disease caused by acid sphingomyelinase deficiency (ASMD), which catalyzes the hydrolysis of sphingomyelin (SM) to ceramide and phosphocholine.
Basics of hyperlipoproreinemia in an easy and understandable way.gives a brief picture of the disease , it's cauusitive agents and clinical sequelae following it.
Comprehensive description of various primary dyslipidemias, cholesterol transport and molecular mechanisms involved.
View in slideshow after downloading for better experience.
Prepared in Dec 2013.
This presentation will show the diagnosttic criteria of metabolic syndrome and life style modification to cope up with this common disease .
also shows some quiz for medical students
Serum Protein and Albumin-Globulin RatioASHIKH SEETHY
For MBBS Biochemistry Practical. Explains various methods of protein estimation and estimation of AG ratio, conditions leading to alterations in AG ratio etc.
Personalized medicine in Familial HypercholesterolaemiaDr. Julius Kwedhi
Familial hypercholesterolemia (FH) is an autosomal-dominant genetic disease present in all racial and ethnic groups and has long been recognized as a cause of premature atherosclerotic coronary heart disease.1–3 Heterozygous FH has the highest prevalence of genetic defects that cause significant premature mortality (≈1:200 to 1:500 or higher in founder populations).
The genetic basis of the disorder, impaired functioning of the low-density lipoprotein (LDL) receptor, was first recognized by Goldstein and Brown4 in their Nobel Prize–winning work.
Studies of LDL receptor function have identified additional mechanisms for the pathogenesis of FH (defects in apolipoprotein [apo] B impairing binding with the LDL receptor and gain-of-function mutations in proprotein convertase subtulisin/kexin type 9 [PCSK9] that enhance LDL receptor degradation).
FH leads to elevated LDL concentrations, with levels in heterozygous FH generally in untreated adults >190 mg/dL LDL cholesterol (LDL-C) and in untreated children or adolescents >160 mg/dL LDL-C. Long-term exposure to elevated plasma concentrations of LDL-C begins in utero, leading in heterozygotes to premature ischemic heart disease in mid adulthood and in homozygotes to ischemic heart disease in childhood or early adulthood.
A lysosomal storage disease caused by acid sphingomyelinase deficiency (ASMD), which catalyzes the hydrolysis of sphingomyelin (SM) to ceramide and phosphocholine.
Basics of hyperlipoproreinemia in an easy and understandable way.gives a brief picture of the disease , it's cauusitive agents and clinical sequelae following it.
Comprehensive description of various primary dyslipidemias, cholesterol transport and molecular mechanisms involved.
View in slideshow after downloading for better experience.
Prepared in Dec 2013.
This presentation will show the diagnosttic criteria of metabolic syndrome and life style modification to cope up with this common disease .
also shows some quiz for medical students
Dyslipidemia, specially high LDL cholesterol is the key risk factor for cardiovascular diseases. The presentation discusses metabolism and structure of lipoproteins, their screening and interpretation, risk assessment methods, targets for various lipoproteins and its step by step treatment.
cardiac bio markers are important diagnostic and prognostic tool in acute coronary syndrome. several new emerging bio markers are coming with more sensitivity and specificity.
differentiating between supraventicular tachycardia and ventricular tachycardia in wide complex rhythm is always confusing and management is totally different. correct diagnosis will make dramatic difference in patient management.
Brugada Syndrome is a inherited sodium channel disorder leading to life threatening ventricular fibrillation in young population. diagnosis and ICD therapy could be life saving.
kawasaki disease is disease of pediatric age group leading to involvement of coronaries in 25% of case. some of presented as fetal complication. early diagnosis and treatment useful measure to prevent complications.
takayasu arteritis is inflammatory disorder of medium sized arteries of unknown etiology, prevent in young female. lead to life threatening complication and long lasting morbidity. early diagnosis and treatment prevent complication and improve quality of life
Trans catheter intervention is emerging field in cardiac intervention. due to complex anatomy of mitral valve understanding of anatomy and three dimensional imaging is most important aspect of successful intervention and could be life saving in high risk surgical candidate
RHD is prevalent in India, many patients requires valve replacement. understanding of prosthetic valve anatomy, morphology and early detection of valve related complication is very important for saving life. TTE and TEE are important tool for identifying these complications.
there are several limitation in VKA,to over come these problem NOACs came in picture but still limited indication for NOACs currently,required further study inter and intra comparison between anticoagulants.
rotablation is procedure used in complex pci with heavily calcified lesion for adequate expansion of stent.if used in indicated case and well aware of contraindication is necessary for achieving good results.
ebstein anomaly is rare congenital disorder,with variable presentation in neonate to adults,early diagnosis and timely take decision make remarkable difference in patients life.
diabetes is most prevalent disease in asia, incidence of heart failure is also increasing in diabetic population, understanding the pathophysiology is very important to deal with these cases.
preop TEE assessment of atrial septal defect is very important for making decision for device closure, properly assessed adequate rims of ASD will reduce risk of device embolization to almost nil.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
2. introduction
• Familial hypercholesterolemia (FH) is autosomal dominant genetic disorder of
lipoprotein metabolism.
• highly elevated plasma total-cholesterol levels associated with detrimental
premature cardiovascular events.
• if left untreated, men and women with heterozygous FH with total cholesterol
levels 310–580 mg/dL typically develop CHD before age 55 and 60.
• homozygotes with total cholesterol levels of 460–1160 mg/dL typically develop
CHD very early in life and if untreated die before age 20.
• among whites, 1/500 are heterozygous for FH and 1/1 000 000 are homozygous.
• prevalence for FH were similar for women and men below age 60.
• above age 60, more women > men s/o men with FH had died at an earlier age.
2
4. • EAS Consensus Panel proposes recommendations on-
• (i) how better to diagnose individuals and families with FH
• (ii) therapeutic strategies for best practice aimed to prevent CHD in these
extremely high-risk individuals and families.
4
6. • mutations in genes encoding key proteins involved in the LDL receptor endocytic
and recycling pathways, leading to decreased cellular uptake of LDL and increased
plasma LDL cholesterol concentrations.
• Cholesterol is packaged into apolipoprotein B-containing very low-density
lipoproteins (VLDL), the intravascular precursors of LDL, which in turn transports
most cholesterol from the liver to peripheral tissues.
• life-threatening effects of both heterozygous and homozygous FH are related to
the resulting elevation in plasma LDL cholesterol, with consequent cholesterol
retention in the arterial wall and foam cell formation within the intima of arteries.
6
7. • Heterozygous FH is caused by-
• heterozygous loss-of function mutations in LDLR
• heterozygous mutations in APOB
• heterozygous gain-of-function mutations in PCSK9.
• Heterozygous LDLR, APOB, and PCSK9 mutations are found in 90%, 5%, and 1%,
respectively, of heterozygous FH subjects with a causative mutation.
• Homozygous FH results from homozygous, or more often, from compound
heterozygous mutations in either the LDLR or ARH genes.
7
8. Whom to screen: how do we recognize index
cases?
• (i) plasma total cholesterol ≥310 mg/dL in an adult or adult family member (or
>95th percentile by age and gender for country)
• (ii) premature CHD in the subject or family member.
• (iii) tendon xanthomas in the subject or family member.
• (iv) sudden premature cardiac death in a family member.
• For child probands, criteria (ii)–(iv) are identical to those of adults.
• criterion (i) should be a plasma total cholesterol ≥230 mg/dL in a child or child
family member( (or >95th percentile by age and gender for country).
8
9. National Health and Nutrition Examination Surveys (NHANESs) reported that the peak lipid levels are reached by
the age of 9-11 years. Therefore, universal screening is best performed between 9 and 11 years of age, whereas
a screening at any time after the age of 2 years is preferred in those who are candidates of targeted screening
9
15. • definite or probable diagnosis of FH (DLCN > 5), and particularly those with an
obvious clinical diagnosis with xanthoma and/or high cholesterol plus a family
history of premature CHD, molecular genetic testing is strongly recommended.
• When a causative mutation is found in the index case, a genetic test should be
offered to all first degree relatives.
15
17. Lifetime risk assessment and risk factors
• risk calculators such as the European SCORE or the US Framingham Risk Score are
not appropriate for FH subjects, as such individuals are at considerably higher risk
due to lifelong LDL cholesterol levels.
• Men develop CHD before women
• hypertension, smoking, diabetes, and high triglycerides/low HDL cholesterol are
all well-established additional risk factors in FH.
• elevated Lp(a) is now a well-established causal risk factor for cardiovascular
disease irrespective of LDL cholesterol concentration
17
19. Cascade, opportunistic, and universal screening
• most cost-effective approach for identification of new FH subjects is cascade
screening of family members of known index case.
• Index cases can be detected by
• opportunistic or targeted systematic screening in primary care guided by a family
history of premature CHD and hypercholesterolemia.
• among patients aged 55/60 in men/women with CHD in hospital settings.
• Another promising but untested targeted approach would be to screen all
children for hypercholesterolemia, for example at a time of infant immunization,
and then, for children with total cholesterol >6 mmol/L (or >95th percentile), to
perform ‘reverse’ cascade screening by testing their parents.
19
20. LDL cholesterol targets
• recommend the following LDL cholesterol targets in FH, in accordance with
recent ESC/EAS guidelines:
• (i) children <135 mg/dL
• (ii) adults <100 mg/dL
• (iii) adults with CHD or diabetes<70 mg/dL.
• above targets are for both heterozygous and homozygous FH regardless of age.
• LDL cholesterol is the primary target of therapy.
• reduction in both cardiovascular and total mortality is proportional to the degree
of LDL cholesterol reduction, with every 1 mmol/L reduction being associated
with a corresponding 22% reduction in cardiovascular mortality and a 12%
reduction in total mortality over 5 years.
20
21. Treatment
• All subjects with FH and their families should undergo intensive education targeting
lifestyle management
• Lifestyle changes-
• Functional foods known to lower LDL cholesterol, such as plant sterols and stanols, may
be considered.
• objective of the nutritional advice is to avoid overweight and to reduce the amount of
food and beverages with high cholesterol, saturated fat, and transfat content.
• low calorie diet with a total fat intake of ≤3% of the total dietary intake including <8% of
saturated fat and <75 mg/1,000 kcal cholesterol.
• Regular physical exercise must be implemented.
• dietary restrictions are noted to have a modest effect in lowering lipid levels, with
unproven long-term clinical benefits.
21
22. • Drug therapy-when to start?-
• recent statement by the American Heart Association,later endorsed by the
American Academy of Pediatrics,statins were proposed as first-line drugs and the
age of initiation of therapy was lowered to 8 years.
• priority for pharmacotherapy should be as follows:
• Children:
• (i) Statin,
• (ii) Ezetimibe
• (iii) Bile acid-binding resin
• (iv) Lipoprotein apheresis in homozygotes.
22
23. • Adults:
• (i) Maximal potent statin dose
• (ii) Ezetimibe
• (iii) Bile acid-binding resins
• (iv) Lipoprotein apheresis in homozygotes and in treatment resistant
heterozygotes with CHD.
23
26. • Maximal potent statin dose should be started at first consultation in adults and could be either
atorvastatin 80 mg, rosuvastatin 40 mg, or pitavastatin 4 mg
• We recommend initiation with maximal potent statin dose in adults with FH because among
subjects with FH:
• (i) <20% achieve the recommended LDL cholesterol targets
• (ii) most need to decrease LDL cholesterol by at least 50%
• (iii) many receive statin doses insufficient to attain LDL cholesterol targets
• (iv) many physicians do not up titrate statin doses despite suboptimal treatment.
• Clinical assessment of efficacy and safety is advisable 4–6 weeks after initiating treatment.
• Statins are the drug of first choice because of the huge and robust body of evidence for statin-
mediated reduction in major cardiovascular events.
26
28. • Despite use of the highest doses of potent statins, many subjects with FH will not
achieve the LDL cholesterol target with monotherapy alone.
• despite lack of demonstrated clinical benefit in FH of co administration of the
cholesterol absorption inhibitor, ezetimibe, add-on to statin therapy in view of
few side effects and high compliance.
• bile acid-binding resin (cholestyramine, colestipol, or colesevelam) as a third
drug is advised.
• elevated triglycerides and low HDL cholesterol or with triglycerides >500 mg/dL
maximal potent statin dose combined with fibrates can be considered.
28
29. Newer drug
• Mipomirsen, an antisense oligonucleotide that targets apoB-100 mRNA in the liver, is presently
under investigation in the therapy of FH.
• Lomitapide is a new lipid-lowering agent
• inhibits the microsomal triglyceride transfer protein(MTP).
• role of MTP in the production of LDL involves assisting in the transfer of triglycerides to
apolipoprotein B.
• US FDA has approved of its use as an orphan drug in the treatment of HoFH.
29
30. • lipoprotein apheresis-
• individuals with FH in extreme cases at very high cardiovascular risk with CHD,
• very high LDL cholesterol levels despite drug therapy or because of statin intolerance
• particularly relevant for children with homozygous FH.
• Weekly or bi-weekly lipoprotein apheresis can decrease LDL cholesterol and Lp(a) by 50–75% and
has clinical benefits in individuals with severe FH.
30
31. Children with familial hypercholesterolemia
• optimal age range for screening is between 2 and 10 years.
• there are no safety data on the use of statins before age 8–10.
• If total or LDL cholesterol is high, a second lipid profile after 2 or 3 months of dietary guidance,
along with other biochemical analyses to exclude secondary hyperlipidemia
• risk factors such as Lp(a), should be performed.
• Once hypercholesterolemia has been detected in the child, it is important to establish its vertical
transmission through a family pedigree.
• Genetic tests should be performed in all children of parents with FH and a causative mutation,
irrespective of whether or not they have high LDL cholesterol.
• children, xanthomas and corneal arcus are not reliable clinical criteria as they only appear later
however, if present, they are suggestive of homozygous FH.
31
33. conclusion
• FH are at severe risk for premature CVD and need to be treated early.
• biggest difficulty is diagnosing the disorder in the asymptomatic population in
order to commence early treatment.
• Cascade screening is useful for identification of case.
• For severe FH, potential novel therapies include inhibitors of MTP and ApoB
mRNA and infusion of pre-beta HDL (CER-001), whereas PCSK9 inhibitors and
CETP inhibitors still require investigation in this condition.
33